Golden
Eligo Bioscience

Eligo Bioscience

Biotherapeautics company founded in 2014 and based in Paris that uses proprietary methods in synthetic biology, protein and genome engineering to produce Eligobiotics, products which intervene with the microbiome as diagnostics, antimicrobials and modulators of host-microbiome interactions.

Eligo Bioscience formed based on research from the Lu Lab at MIT and the Marraffini Lab at Rockefeller University. From 2014-2017 Eligo was incubated at the Institut Pasteur in Paris and now resides at the Paris Biotech Santé at Cochin Hospital.

Eligo Bioscience develops Eligobiotics, which are nano-delivery vehicles that are based on non-replicative phage particles that are engineered and programmed to package synthetic genetic circuits.

In 2014 two Nature Biotechnology papers by group members describe programmable, sequence-specific antimicrobials that use CRISPR-Cas9 system with the potential to manipulate complex bacterial populations. Eligo describes these types of targeted antimicrobials as “Editing the microbiome”. Their antimicrobials do not edit bacterial DNA, rather the delivered CRIPSR-Cas system cuts up and destroys the DNA of the target bacteria.The group has used their system to selectively remove a specific strain of bacteria from the gut of mice while keeping the other microflora intact.

Timeline

People

Name
Role
Related Golden topics

Dr. David Bikard

Co-Founder

Dr. Xavier Duportet

Co-Founder

Prof. Luciano Marraffini

Co-Founder

Prof. Timothy Lu, MD-PhD

Co-Founder

Further reading

Title
Author
Link
Type

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References